HepB3 transfection, HepG2 transfection and SNU449 transfection with miRNA and siRNA were performed using the Magnetofectamine transfection kit.
This paper demonstrated the high efficiency of Magnetofectamine from OZ Biosciences to transfect hepatic cancer cell lines (HepB3, HepG2 and SNU449).paper reference: PLoS One. 2013 Apr 10;8(4):e61054.
Underexpression of miR-34a in Hepatocellular Carcinoma and Its Contribution towards Enhancement of Proliferating Inhibitory Effects of Agents Targeting c-MET.Dang Y, Luo D, Rong M, Chen G.
Abstract
Aberrant expression
of microRNA-34a (miR-34a) has been reported to be involved in the
tumorigenesis and progression of various classes of malignancies.
However, its role in hepatocellular carcinoma (HCC) has not been
completely clarified. In the current study, we have investigated the
clinical significance and the in vitro contribution of miR-34a on
biological functions of human HCCs. miR-34a expression in eighty-three
cases of HCC formalin-fixed paraffin-embedded (FFPE) tissues decreased
significantly compared to that in the adjacent liver tissues
(P<0.01), as detected by real-time quantitative RT-PCR (RT-qPCR).
miR-34a expression in the groups of TNM stage I and II, without
metastasis and without portal vein tumor embolus, was significantly
higher than that of their corresponding groups (P<0.05). In
functional experiments, miR-34a mimic suppressed cell growth, migration
and invasion, meanwhile it increased cellular apoptosis and caspase
activity in HCC cells. miR-34a mimic also reduced phospho-ERK1/2 and
phospho-stat5 signaling. In addition, miR-34a mimic enhanced the effect
of cell proliferation inhibition and caspase activity induction of
agents targeting c-MET (siRNAs and small molecular inhibitor su11274).
In conclusion, miR-34a may act as a tumor suppressor miRNA of HCC. The
strategies to increase miR-34a level might be a critical targeted
therapy for HCC in future.
No comments:
Post a Comment